... “wild type,” as well as pediatric GISTs, do not often respond well to treatment with Gleevec.
The Fox Chase researchers found that, when compared to mutant GISTs, the DNA of wild type and pediatric ...
... the clinical trial in human patients in Sweden bears out the findings seen in mice, perhaps Gleevec could be given immediately upon suspicion of stroke-like symptoms, before diagnostic scans and other ...
... certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family. The research will be presented Monday, Dec. 8, ...
... gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these ...
... researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease ...
... cancers such as multiple myeloma,” said Dr. Anuradha Ray. “Collectively, similar approaches to inhibit c-Kit, in addition to Gleevec or other inhibiting compounds could alleviate multiple cancers.”
... Gleevec does dramatically improve prognosis of CML patients,” notes Pandolfi. “But, unfortunately, Gleevec is not curative in most cases. Because it targets only dividing cells, the pool of quiescent ...
... of drug development strategies for years, with some protein kinase-inhibiting compounds, such as Gleevec, already being used clinically to inhibit tumor growth. Though pharmaceutical companies have a ...
... specific genetic abnormality and is one of the more common forms of leukemia. Imatinib mesylate, or Gleevec, is a highly effective anti-cancer agent that has revolutionized the course of therapy for ...
... for melanoma patients with metastatic disease. But not all melanomas respond so successfully to Gleevec.
In the current study, Heinrich and colleagues studied 129 samples gathered from people with ...
... may be particularly beneficial for patients who are resistant to small molecule kinase inhibitors like Gleevec as resistant isoforms of ABL and BCR-ABL should contain the target site for miR-203 and ...
CHICAGO (Reuters) - Leukemia patients may be able to avoid developing resistance to the drug Gleevec through a mathematical formula that predicts when they should receive an immune-boosting vaccine, ...
Activation of LYN kinase is associated with resistance to imatinib (Gleevec) in patients with chronic myelogenous leukemia (CML), researchers report in the June 24 online issue of the Journal of the ...
... control kinases are a major cause of cancer. Many successful cancer drugs — such as Gleevec, which is used for the treatment of leukemia, — specifically target wayward tyrosine kinases.
This treasure ...
... reattach, genes fuse giving rise to chimeric RNA, which in turn is used to construct the chimeric protein. Gleevec, a highly successful new anti-cancer drug, was developed to target the chimeric ...
